NASDAQ: NVCTNuvectis Pharma Inc Stock Ownership - Who owns Nuvectis Pharma?
Insider buying vs selling
Have Nuvectis Pharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ron Bentsur | Chairman CEO | 2026-06-30 | 12,500 | $20.00 | $250.00kBuy |
| Marlio Charles Mosseri | 10% Owner | 2026-06-30 | 50,000 | $18.32 | $916.00kBuy |
| Ron Bentsur | Chairman CEO | 2025-11-05 | 5,000 | $5.72 | $28.60kBuy |
| Matthew L. Kaplan | Director | 2025-11-05 | 11,000 | $5.84 | $64.24kBuy |
| Juan Sanchez | Director | 2025-11-05 | 13,000 | $5.79 | $75.27kBuy |
| Marlio Charles Mosseri | 10% Owner | 2025-10-27 | 72,836 | $6.28 | $457.41kBuy |
| Marlio Charles Mosseri | 10% Owner | 2025-10-24 | 35,034 | $6.15 | $215.46kBuy |
| Marlio Charles Mosseri | 10% Owner | 2025-10-23 | 46,900 | $6.06 | $284.21kBuy |
NVCT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when NVCT insiders and whales buy or sell their stock.
NVCT Shareholders
What type of owners hold Nuvectis Pharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ron Bentsur | 11.32% | 3,688,424 | $81.15M | Insider |
| Marlio Charles Mosseri | 10.12% | 3,295,897 | $72.51M | Insider |
| Enrique Poradosu | 5.54% | 1,806,319 | $39.74M | Insider |
| Shay Shemesh | 5.50% | 1,793,068 | $39.45M | Insider |
| Michael J. Carson | 0.71% | 230,118 | $5.06M | Insider |
| Kenneth Hoberman | 0.52% | 168,140 | $3.70M | Insider |
| Matthew L. Kaplan | 0.49% | 159,760 | $3.51M | Insider |
| James F. Oliviero Iii | 0.38% | 122,828 | $2.70M | Insider |
| Juan Sanchez | 0.35% | 113,795 | $2.50M | Insider |
| URI Benor | 0.08% | 25,584 | $562.85k | Insider |
NVCT vs Biotech Stocks
Nuvectis Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.